EBS: חוב לטווח קצר להון עצמי emergentbiosolutions.com

Emergent BioSolutions (EBS) specializes in developing antidotes and vaccines to protect against bioterrorism. The market capitalization trend confirms the completely non-cyclical nature of the business, which relies on stable US government contracts. The current figure is 0.21. Facilities are located domestically, and their operations are guaranteed by national security agreements. While the Pentagon serves as the primary customer, past product quality issues triggered FDA sanctions.

The workforce transformation at Emergent BioSolutions (EBS) requires strict liquidity control to retain key bioengineers. This ratio measures the proportion of current liabilities within the equity structure, revealing the company's dependence on external debt financing. The daily price action of short-term liabilities relative to equity on this chart demonstrates the risk of cash flow gaps. An increase in this metric signals a critical weakening of the business's financial stability.